Zymeworks to Participate in Upcoming Investor Conferences and Events
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, announced today
that management will participate in five upcoming virtual investor
- Guggenheim Healthcare Talks Oncology Days, February 11-12,
2021. Zymeworks will be participating in the event; there is no
- SVB Leerink’s 10th Annual Global Healthcare Conference,
February 22-26, 2021. Zymeworks will be participating in the
conference, there is no public presentation.
- Raymond James’ 42nd Annual Institutional Investor Conference,
March 1-3, 2021. Zymeworks will be participating in the conference;
there is no public presentation.
- Barclays’ Global Healthcare Conference, March 9-11, 2021.
Zymeworks is presenting on Thursday, March 11, 2021 at 1:15 p.m.
- Citi's 2021 Winter West Coast Biotech Virtual Bus Tour, March
16-17, 2021. Zymeworks will be participating in the event; there is
no public presentation.
Interested parties can access a live webcast of the Barclays
presentation via a link from Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations, which will also
host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab (ZW25), is a novel Azymetric™
bispecific antibody which has been granted Breakthrough Therapy
designation by the FDA and is currently enrolling in a pivotal
clinical trial for refractory HER2-amplified biliary tract cancer
(HERIZON-BTC-01) as well as several Phase 2 clinical trials for
HER2-expressing gastroesophageal and breast cancers. Zymeworks’
second clinical candidate, ZW49, is a novel bispecific
HER2-targeting antibody-drug conjugate currently in Phase 1
clinical development and combines the unique design and antibody
framework of zanidatamab with Zymeworks’ proprietary ZymeLink™
linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
version on businesswire.com: https://www.businesswire.com/news/home/20210210005760/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
Tiffany Tolmie (604) 678-1388 email@example.com
Media Inquiries: Mary Klem (604) 678-1388
Historical Stock Chart
From Sep 2021 to Oct 2021
Historical Stock Chart
From Oct 2020 to Oct 2021